Know Cancer

or
forgot password
  • cancer clinical trials in boston, MA

  • Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
    Massachusetts General Hospital

    Trial Locations
    Massachusetts General Hospital
    Boston Children's Hospital
    Hepatic Veno-Occlusive Disease
    Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Dana-Farber/Brigham and Women's Cancer Center
    Lung Cancer
    Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
    Tufts Medical Center
    Boston, Massachusetts 02111
    Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
    A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
    Children's Hospital Boston
    Boston, Massachusetts 02115
    Neurofibromatosis Type 1
    Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
    Dana Farber Cancer Institute

    Trial Locations
    Dana Farber Cancer Institute
    Dana-Farber Cancer Inst
    Dana Farber Cancer Inst
    High Risk Stage III Melanoma
    Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Non-small Cell Lung Cancer
    CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215
    Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms, Cancer of the Prostate
    Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Low Grade B-cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large-cell Lymphoma
    Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
    Boston Medical Center
    Boston, Massachusetts 02118
    Bladder Cancer
    N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
    Children's Hospital Boston
    Boston, Massachusetts 02115
    Neuroblastoma
    Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
    Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
    Massachusetts General Hospital

    Trial Locations
    Massachusetts General Hospital
    Boston University Cancer Research Center
    Leukemia
    Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    EGFR Inhibitor-associated Rash
    Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Neurofibromatosis Type 1, Cutaneous Neurofibromas
    Dose-Intense Temozolomide in Recurrent Glioblastoma
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Tufts-New England Medical Center
    Glioblastoma, Gliosarcoma
    Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising PSA After Local Therapy
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Prostate Cancer
    Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
    Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Tobacco Use Disorder
    Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
    Massachusetts General Hospital

    Trial Locations
    Massachusetts General Hospital
    DFCI
    Esophageal Adenocarcinoma, Gastric Adenocarcinoma
    Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Kidney Cancer, Leukemia, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
    A Phase II Study of Umbilical Cord Blood Transplantation
    Tufts Medical Center
    Boston, Massachusetts 02111
    Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia
    Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
    Boston University Cancer Research Center
    Boston, Massachusetts 02118
    Multiple Myeloma and Plasma Cell Neoplasm
    High-Dose Melphalan and Stem Cell Transplant in Treating Patients With Immunoglobulin Deposition Disease or Light-Chain Deposition Disease
    Boston University Cancer Research Center
    Boston, Massachusetts 02118
    Multiple Myeloma and Plasma Cell Neoplasm
    Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Low Grade Gliomas
    Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Massachusetts General Hospital
    Dana-Farber Cancer Institute/Brigham and Women's Hospital
    Prostate Cancer
    Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
    Massachusetts General Hospital Cancer Center

    Trial Locations
    Massachusetts General Hospital Cancer Center
    Dana Farber Cancer Institute
    Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center
    Solid Tumors
    Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Glioma
    Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer
    Boston Medical Center

    Trial Locations
    Boston Medical Center
    Massachusetts General Hospital
    Ductal Breast Cancer
    Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Advanced Malignancies